6185.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 11:08):

Stats
Šios dienos apimtis	1.23M
Vidutinė apimtis	1.10M
Rinkos kapitalizacija	8.19B
EPS	HKD-0.580 ( 2023-10-30 )
Last Dividend	HKD0.937 ( 2022-07-13 )
Next Dividend	HKD0 ( N/A )
P/E	-3.26
ATR14	HKD0.0460 (0.22%)

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: 0.50 (neutral)

Signal:(66.263) Neutral

Cansino Biologics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Cansino Biologics Inc Koreliacija - Valiuta/Žaliavos

0.19
( neutral )

0.31
( neutral )

-0.57
( weak negative )

0.25
( neutral )

-0.26
( neutral )

-0.53
( weak negative )

Cansino Biologics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	HKD345.18M
Bruto pelnas:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2023
Pajamos:	HKD345.18M
Bruto pelnas:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2022
Pajamos:	HKD1.03B
Bruto pelnas:	HKD-186.61M (-18.10 %)
EPS:	HKD-3.91

FY	2021
Pajamos:	HKD4.30B
Bruto pelnas:	HKD3.00B (69.85 %)
EPS:	HKD7.74

Financial Reports:

No articles found.

Cansino Biologics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.937 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Cansino Biologics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.937	2022-07-13
Last Dividend	HKD0.937	2022-07-13
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	HKD0.937	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-02)

HKD0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6119.HK	Ex Dividend Knight	2023-06-06	Annually	0.00%
1858.HK	Ex Dividend Junior	2023-06-30	Annually	0.00%
0882.HK	Ex Dividend Knight	2023-09-25	Semi-Annually	0.00%
0026.HK	Ex Dividend Junior	2023-10-03	Semi-Annually	0.00%
2682.HK	Ex Dividend Junior	2023-09-04	Annually	0.00%
1432.HK	Ex Dividend Junior	2023-06-19	Insufficient data to determine frequency	0.00%
0520.HK	Ex Dividend Junior	2023-10-05	Semi-Annually	0.00%
6881.HK	Ex Dividend Junior	2023-07-11	Annually	0.00%
1978.HK	Ex Dividend Knight	2023-09-14	Annually	0.00%
1038.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-4.24	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.159	1.200	-5.30	-6.36	[0 - 0.3]
returnOnEquityTTM	-0.252	1.500	-3.91	-5.86	[0.1 - 1]
payoutRatioTTM	-0.0725	-1.000	-0.725	0.725	[0 - 1]
currentRatioTTM	1.999	0.800	5.01	4.00	[1 - 3]
quickRatioTTM	1.835	0.800	3.91	3.13	[0.8 - 2.5]
cashRatioTTM	0.790	1.500	6.72	10.00	[0.2 - 2]
debtRatioTTM	0.290	-1.500	5.17	-7.76	[0 - 0.6]
interestCoverageTTM	-37.09	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-3.62	2.00	-1.207	-2.41	[0 - 30]
freeCashFlowPerShareTTM	-6.10	2.00	-3.05	-6.10	[0 - 20]
debtEquityRatioTTM	0.512	-1.500	7.95	-10.00	[0 - 2.5]
grossProfitMarginTTM	-1.411	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-3.70	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.330	1.000	-2.95	-2.95	[0.2 - 2]
assetTurnoverTTM	0.0376	0.800	-3.08	-2.47	[0.5 - 2]
Total Score				-3.45

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.98	1.000	-0.402	0	[1 - 100]
returnOnEquityTTM	-0.252	2.50	-2.51	-5.86	[0.1 - 1.5]
freeCashFlowPerShareTTM	-6.10	2.00	-2.03	-6.10	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-3.62	2.00	-1.207	-2.41	[0 - 30]
payoutRatioTTM	-0.0725	1.500	-0.725	0.725	[0 - 1]
pegRatioTTM	0.173	1.500	-2.18	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-2.55	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.75

Cansino Biologics Inc

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.